F-Prime
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Tenpoint Therapeutics unlocks a £170m Series B from investors to rejuvenate vision in the aging eye
Tenpoint Therapeutics develops treatments for age-related eye conditions. Its products are designed to address presbyopia and other vision issues through clinically developed ophthalmic therapies.
T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.
Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug
Charm Therapeutics develops next generation cancer drugs designed to overcome treatment resistance, using an AI driven discovery platform to identify compounds for aggressive blood cancers such as AML.
KKR leads £300m Series C for Lighthouse to accelerate AI-driven growth in the hospitality tech market
Lighthouse provides AI-powered commercial intelligence software for hotels and hospitality groups, analysing large volumes of market and performance data to help operators optimise pricing, distribution, operations and guest experience across thousands of properties globally.
More venture news
- 1 Apr 2026
Sona secures a £34m Series B led by N47 for workforce management software focussed on frontline businesses
Series BEnterprise - 26 Mar 2026
Giraffe360Giraffe360 secures a £7.5m Series B led by Cipio Partners for real estate marketing tech
Series BProperty - 18 Feb 2026
FYLD secures a £30m Series B led by Energy Impact Partners to monitor high-risk infrastructure fieldwork with intelligence platform
Series BIndustrial
